BY MARKETWIRE
-
Analyst on Eli Lilly lower price weight loss drug: Aimed at limited part of the market
” You’re not all of a sudden interfering with a whole market with this,” expert quotes.
-
Sonova launches first AI hearing aid
Information recommends that the brand-new item raises the signal to sound proportion by 10 decibels.
-
J&J receives expanded EU approval for Genmab lung cancer drug
Genmab is receiving excessive single-digit and as much as double-digit royalties from the sale of the lung most cancers drug.
-
WS Audiology delivers double-digit organic growth in Q3
Organic development in the 3rd quarter, which covers the fiscal year’s 2nd quarter, was 12%, according to the producer’s quarterly record.
-
GN Hearing posts 10% organic growth in Q2
Income margins, nonetheless, disappoint expert estimates.
-
WS Audiology delivers double-digit organic growth in Q3
Organic growth in the third quarter, which covers the calendar year’s second quarter, was 12%, according to the manufacturer’s quarterly report.
-
4 ways to achieve early wins with AI in marketing
Incorporate AI right into your advertising approach with these sensible, step-by-step actions that drive actual outcomes.The article 4 means to attain very early success with AI in…
-
Eli Lilly’s obesity drug reduces risk of pre-diabetic patients developing disease, study finds
One examine exhibits that Zepbound reduces the chance that pre-diabetics will develop sort 2 diabetes by 94% and ends in 22.9% weight reduction.
-
Kepler predicts better 2025, improves Demant recommendation
The monetary solutions business has actually transformed its suggestion to “hold” from “decrease”.
-
Analyst: No room for error at Coloplast as reimbursement questions linger
Coloplast is launching its Q3 record for the 2023/24 bookkeeping duration tomorrow early morning at 07:30.
